Abstract:Background: Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog) contributes to human tumorigenesis via epigenetic transcriptional silencing and represents a novel therapeutic target with great potentials. Here we sought to determine the therapeutic efficiency of PTC-209, a potent and selective Bmi1 inhibitor, in head neck squamous cell carcinoma (HNSCC) cells and a HNSCC xenograft model. Methods: The mutation pattern, mRNA level of Bmi1 in HNSCC and its associations with clinicopathological parameters were determined through comprehensive data mining and interrogation using publicly available databases GENT, cBioPortal, Oncomine and TCGA. The PTC-209, a selective and potent Bmi1 inhibitor, was exploited and its effect on Bmi1 expression was measured in two HNSCC cell lines Cal27 and FaDu. The phenotypical changes of HNSCC cells were observed upon PTC-209 treatment in vitro. Moreover, the therapeutic effects of PTC-209 for HNSCC were determined in a xenograft animal model. Results: Through comprehensive data mining and interrogation, we found that Bmi1 mRNA was frequently over-expressed in a subset of HNSCC samples. Our data revealed that PTC-209 robustly reduced the expression of Bmi1 in Cal27 and FaDu cells presumably by post-transcriptional repression and ubiquitin-proteasomal degradation. PTC-209 treatment resulted in impaired cell proliferation, G1-phase cell cycle arrest, compromised migration and invasiveness, and increased cell apoptosis and chemosensitivity to 5-FU and cisplatin in vitro. Moreover, PTC-209 exposure reduced colony formation, tumorsphere formation and the percentage of ALDH1(+) subpopulation in both Cal27 and FaDu cells. Importantly, in vivo PTC-209 administration significantly reduced tumor growth in a HNSCC xenograft model probably by Bmi1 inhibition and impaired cell proliferation. Conclusions: Our findings indicate that pharmacological inhibition of Bmi1 is a novel therapeutic strategy for HNSCC patients, especially with those with aberrant Bmi1 overexpression.

Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.

Biomarkers Of Head And Neck Cancer Stem Cells And Targeted Therapeutic Strategies

Cancer stem cell self-renewal as a therapeutic target in human oral cancer

Generation of a Squamous Cell Carcinoma Mouse Model for Lineage Tracing of BMI1+ Cancer Stem Cells

The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells

Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma

METTL3-mediated ALDH M6a Methylation Regulates the Malignant Behavior of BMI1+ HNSCC Stem Cells

Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade

Pharmacological Inhibition of Bmi1 by PTC-209 Impaired Tumor Growth in Head Neck Squamous Cell Carcinoma

Targeting Cancer Stem Cells In Squamous Cell Carcinoma

Targeting Cellular Metabolism in Head and Neck Cancer Precision Medicine Era: A Promising Strategy to Overcome Therapy Resistance

NOTCH1 Inhibition Enhances the Efficacy of Conventional Chemotherapeutic Agents by Targeting Head Neck Cancer Stem Cell

Bmi1 Severs As a Potential Tumor-Initiating Cell Marker and Therapeutic Target in Esophageal Squamous Cell Carcinoma

Targeting HIF-1α/NOTCH1 pathway eliminates CD44+ cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma

BMI1'S Maintenance of the Proliferative Capacity of Laryngeal Cancer Stem Cells

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Identification of tumor stemness and immunity related prognostic factors and sensitive drugs in head and neck squamous cell carcinoma

CD276 Expression Enables Squamous Cell Carcinoma Stem Cells to Evade Immune Surveillance.

Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC

Polycomb Complex Protein Bmi-1 Promotes Invasion and Metastasis of Pancreatic Cancer Stem Cells by Activating Pi3k/Akt Signaling, an Ex Vivo, in Vitro, and in Vivo Study